ERAP2 and cancer: Our work suggests that, in cancer cells, ERAP2 plays important roles in limiting presentation of cancer antigens and thus pharmacological inhibition by DG011A or similar inhibitors may be a viable approach to modulating the cancer immunopeptidome for immunotherapy applications.